Sign in Subscribe

metastatic

A collection of 142 issues

Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer A Phase II study tested pembrolizumab plus capecitabine and bevacizumab in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer, a population that typically does not respond well to immunotherapy alone. (Clinical

CRC Research Update — August 10, 2026

Today's colorectal cancer research highlights

Metastatic Colon Cancer Reported in 15-Year-Old Patient

Skip to content The CRC Digest Metastatic Colon Cancer Reported in 15-Year-Old Patient A case report describes a 15-year-old with metastatic colon adenocarcinoma presenting with abdominal pain, highlighting that colorectal cancer is extremely rare in children and often associated with genetic predisposition syndromes such as Lynch syndrome or familial adenomatous

CRC Research Update — August 09, 2026

Today's colorectal cancer research highlights

Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)

COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer A new analysis examines what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. (Journal of Clinical Oncology)

CRC Research Update — August 07, 2026

Today's colorectal cancer research highlights

Direct visualization system aids stent placement in 39-year-old with malignant obstruction

Skip to content The CRC Digest Direct visualization system aids stent placement in 39-year-old with malignant obstruction A case report describes successful use of a direct visualization device to guide enteral stent placement across a stenotic sigmoid colon tumor in a 39-year-old woman with intestinal obstruction. (Frontiers in Medicine) This

Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC This single-arm phase II study investigated whether patients with refractory metastatic colorectal cancer who previously responded to irinotecan could benefit from high-dose irinotecan rechallenge, with dosing adjusted based on

Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases

Skip to content The CRC Digest ▸ TREATMENT Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients